

Financial news for ICPT dated on 2020-06-05: Benzinga's Top Upgrades, Downgrades For June 5, 2020

Financial news for ICPT dated on 2020-06-05: BMO Capital Initiates Coverage On Intercept Pharmaceuticals with Outperform Rating, Announces Price Target of \$107

Financial news for ICPT dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for ICPT dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for ICPT dated on 2020-05-22: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for ICPT dated on 2020-05-22: Hearing Raymond James Downgraded Intercept Pharmaceuticals From Strong Buy To Outperform; Unconfirmed

Financial news for ICPT dated on 2020-05-22: Intercept Notified BY FDA That AdCom Meeting For Obeticholic Acid NDA Has Been Postponed

Financial news for ICPT dated on 2020-05-12: Stifel Maintains Hold on Intercept Pharmaceuticals, Lowers Price Target to \$99

Financial news for ICPT dated on 2020-05-11: Recap: Intercept Pharmaceuticals Q1 Earnings

Financial news for ICPT dated on 2020-05-11: Intercept Pharmaceuticals Q1 EPS \$(2.860) Beats \$(2.950) Estimate, Sales \$72.652M Beat \$69.660M Estimate

Financial news for ICPT dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for ICPT dated on 2020-04-07: Analyst Projects Over 130% Upside In This Biopharma

Financial news for ICPT dated on 2020-04-02: Benzinga's Top Upgrades, Downgrades For April 2, 2020

Financial news for ICPT dated on 2020-04-02: Chardan Capital Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces Price Target to \$145

Financial news for ICPT dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for ICPT dated on 2020-03-26: Intercept Pharmaceuticals Inc Says Prescription Drug User Fee Act Target Action Date For NDA Remains June 26, 2020

Financial news for ICPT dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest-stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for ICPT dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for ICPT dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for ICPT dated on 2020-03-05: B of A Securities Initiates Coverage On Intercept Pharmaceuticals with Neutral Rating, Announces \$111 Price Target

Financial news for ICPT dated on 2020-02-26: Citigroup Upgrades Intercept Pharmaceuticals to Buy

Financial news for ICPT dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for ICPT dated on 2020-02-25: Intercept Pharmaceuticals Q4 EPS \$(2.99) Misses \$(2.62) Estimate, Sales \$71.5M Beat \$68.42M Estimate

Financial news for ICPT dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for ICPT dated on 2020-02-21: SVB Leerink Upgrades Intercept Pharmaceuticals to Market Perform

Financial news for ICPT dated on 2020-02-05: 13 Key NASH Drug Candidates To Watch For In A Potential \$30-Billion Market

Financial news for ICPT dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for ICPT dated on 2020-01-29: Intercept Reports Completion Of Enrollment For Phase 3 REVERSE Study Evaluating Obeticholic Acid For Treatment Of Compensated Cirrhosis Due To NASH

Financial news for ICPT dated on 2020-01-17: Intercept 8-K Shows FDA Notified Co. Of Extension For PDUFA Target Action Date To Jun. 26, 2020

Financial news for ICPT dated on 2020-01-09: B. Riley FBR Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to \$158

Financial news for ICPT dated on 2020-01-02: Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In

Financial news for ICPT dated on 2020-01-02: 10 Biggest Price Target Changes For Thursday

Financial news for ICPT dated on 2020-01-02: Citigroup Downgrades Intercept Pharmaceuticals to Neutral, Raises Price Target to \$140

Financial news for ICPT dated on 2019-12-17: Credit Suisse Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to \$141

Financial news for ICPT dated on 2019-12-17: Wells Fargo Maintains Overweight on Intercept Pharmaceuticals, Raises Price Target to \$146

Financial news for ICPT dated on 2019-12-13: Intercept Pharma Offers Regulatory Update: Co. Submitted Marketing Authorization Application To EMA, FDA Notified Co. Of Tentative Date For AdCom Panel As Apr. 22, 2020

Financial news for ICPT dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for ICPT dated on 2019-12-06: 55 Stocks Moving In Friday's Mid-Day Session

Financial news for ICPT dated on 2019-12-06: Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

Financial news for ICPT dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ICPT dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ICPT dated on 2019-11-25: Intercept Pharma Reports FDA Accepted New Drug Application For Obeticholic Acid For Treatment Of Liver Fibrosis Due To NASH, Has Granted Priority Review

Financial news for ICPT dated on 2019-11-12: UBS Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to \$135

Financial news for ICPT dated on 2019-11-06: RBC Capital Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to \$134

Financial news for ICPT dated on 2019-11-05: Intercept Pharmaceuticals Q3 EPS \$(2.59) Misses \$(2.43) Estimate, Sales \$61.95M Miss \$63.33M Estimate

Financial news for ICPT dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for ICPT dated on 2019-10-25: Hearing Dealreporter Says Gilead Could Be Eyeing Intercept Pharma

Financial news for ICPT dated on 2019-10-21: Raymond James Maintains Strong Buy on Intercept Pharmaceuticals, Lowers Price Target to \$147

Financial news for ICPT dated on 2019-10-10: Stocks That Hit 52-Week Lows On Thursday

Financial news for ICPT dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for ICPT dated on 2019-10-08: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ICPT dated on 2019-09-27: Intercept Pharma Reports Submitted New

Drug Application For Obeticholic Acid in Patients with Fibrosis Due to NASH

Financial news for ICPT dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ICPT dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ICPT dated on 2019-09-04: Benzinga's Top Upgrades, Downgrades For September 4, 2019

Financial news for ICPT dated on 2019-09-04: Citigroup Upgrades Intercept Pharmaceuticals to Buy, Lowers Price Target to \$85

Financial news for ICPT dated on 2019-08-30: Intercept Pharmaceuticals, Inc.: Akkaraju Srinivas (Director) Buys 5,207 @ Avg Price: \$60.32

Financial news for ICPT dated on 2019-08-08: Intercept Pharma shares continuing higher following Q2 earnings Wednesday morning. Shares have broken above the \$62 level today.

Financial news for ICPT dated on 2019-08-08: Cantor Fitzgerald Reiterates Overweight on Intercept Pharmaceuticals, Lowers Price Target to \$186

Financial news for ICPT dated on 2019-08-07: Intercept Pharmaceuticals Q2 EPS \$(2.28) Beats \$(2.6) Estimate, Sales \$66.3M Beat \$58.6M Estimate

Financial news for ICPT dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for ICPT dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for ICPT dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for ICPT dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for ICPT dated on 2019-08-01: Stocks that Reached Yearly Lows Thursday Morning

Financial news for ICPT dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for ICPT dated on 2019-07-31: New 52-Week Low Achievers For Wednesday Morning

Financial news for ICPT dated on 2019-07-26: Stocks That Managed to Breach 52-Week Lows Friday

Financial news for ICPT dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for ICPT dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for ICPT dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for ICPT dated on 2019-07-12: The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study

Financial news for ICPT dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for ICPT dated on 2019-07-11: 50 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-07-10: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ICPT dated on 2019-06-25: Stifel Nicolaus Initiates Coverage On Intercept Pharmaceuticals with Hold Rating, Announces \$89 Price Target

Financial news for ICPT dated on 2019-06-17: ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention

Financial news for ICPT dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for ICPT dated on 2019-06-13: Intercept Pharma Shares Spike To Session High On Volume As Hearing RBC Commented On Recent Co. CEO Communication With FDA, Definitive Confirmation Histological Endpoints Can Still Form Basis Of Accelerated Approval From Its REVERSE Study

Financial news for ICPT dated on 2019-06-11: Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

Financial news for ICPT dated on 2019-06-06: Baird Out Defending Intercept Pharmaceuticals, Says 'sharp selloff in shares on FDA Draft guidance that doesn't even address the primary commercial opportunity for OCA is silly'

Financial news for ICPT dated on 2019-06-06: ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

Financial news for ICPT dated on 2019-05-23: Intercept Pharma Shares Saw Mid-Day Parabolic Move On Very Large Uptick In Volume Amid Report RBC Suggested The Co. Could Be Worth \$142/Share In A Takeout

Financial news for ICPT dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for ICPT dated on 2019-05-08: Intercept Pharma Reports \$200M Common Stock Offering

Financial news for ICPT dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for ICPT dated on 2019-05-08: Intercept Pharmaceuticals Sees 2019 Ocaliva Sales \$235M-\$245M

Financial news for ICPT dated on 2019-05-08: Intercept Pharmaceuticals Q1 EPS \$(3.03) Misses \$(2.52) Estimate, Sales \$51.85M Beat \$51.8M Estimate

Financial news for ICPT dated on 2019-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2019

Financial news for ICPT dated on 2019-05-03: Wells Fargo Upgrades Intercept Pharmaceuticals, Inc. - Common Stock to Outperform

Financial news for ICPT dated on 2019-04-25: Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment

Financial news for ICPT dated on 2019-04-12: Wells Fargo Maintains Market Perform on Intercept Pharmaceuticals, Raises Price Target to \$104

Financial news for ICPT dated on 2019-04-12: 50 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-04-11: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for ICPT dated on 2019-04-11: Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event?

Financial news for ICPT dated on 2019-04-11: Intercept Pharmaceuticals Option Alert: Jun 21 \$140 Calls at the Ask: 600 @ \$2.5 vs 1718 OI; Earnings 5/7 Before Open [est] Ref=\$107.9022

Financial news for ICPT dated on 2019-04-11: Intercept Pharmaceuticals shares are trading lower, despite the company reporting additional positive data from its REGENERATE phase 3 study in NASH, after investors interpreted this data to be underwhelming and not have much new information.

Financial news for ICPT dated on 2019-04-11: '\$ICPT -- Anyone else disappointed w/ this morning's NASH study update? Not much new to chew over. The per protocol efficacy results seem like marketing material. Safety data essentially same as previously disclosed. Am I missing something?' -STAT's Adam F

Financial news for ICPT dated on 2019-04-11: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for ICPT dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For

Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for ICPT dated on 2019-04-11: Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

Financial news for ICPT dated on 2019-04-07: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for ICPT dated on 2019-04-04: Intercept To Present Results From Phase 3 Trial Patients with Liver Fibrosis Due to NASH at the International Liver Congress(tm) 2019

Financial news for ICPT dated on 2019-03-22: Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

Financial news for ICPT dated on 2019-03-19: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ICPT dated on 2019-03-01: Intercept Pharmaceuticals Option Alert: Mar 15 \$109 Calls at the Ask: 846 @ \$4.401 vs 1018 OI; Ref=\$105.96

Financial news for ICPT dated on 2019-03-01: Raymond James Maintains Strong Buy on Intercept Pharmaceuticals, Raises Price Target to \$187

Financial news for ICPT dated on 2019-03-01: B. Riley FBR Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to \$169

Financial news for ICPT dated on 2019-03-01: Benzinga's Top Upgrades, Downgrades For March 1, 2019

Financial news for ICPT dated on 2019-03-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 1, 2019

Financial news for ICPT dated on 2019-03-01: RBC Capital Upgrades Intercept Pharmaceuticals to Outperform

Financial news for ICPT dated on 2019-03-01: 75 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-02-28: Cantor Fitzgerald Reiterates Overweight on Intercept Pharmaceuticals, Raises Price Target to \$191

Financial news for ICPT dated on 2019-02-28: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for ICPT dated on 2019-02-28: Intercept Pharmaceuticals Inc shares are trading higher after the company beat Q4 sales estimates, despite missing on EPS; the company guided FY19 Ocaliva sales of \$225 million to \$240 million.

Financial news for ICPT dated on 2019-02-28: Intercept Sees FY19 Ocaliva Sales \$225M-\$240M

Financial news for ICPT dated on 2019-02-28: Intercept Pharmaceuticals Q4 EPS \$(2.97) Misses \$(2.47) Estimate, Sales \$53.28M Beat \$52.28M Estimate

Financial news for ICPT dated on 2019-02-28: '\$ICPT says eDISH plot for REGENERATE looks v similar to FLINT. 3 on pbo entered Hy's law quadrant, vs total of 3 btwn low/high dose OCA' -Tweet From Notable FDA Source

Financial news for ICPT dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for ICPT dated on 2019-02-21: Intercept Pharmaceuticals Option Alert: Mar 1 \$100 Calls at the Ask: 600 @ \$2.0 vs 42 OI; Earnings 2/25 Before Open [est] Ref=\$90.9199

Financial news for ICPT dated on 2019-02-21: Citigroup Maintains Neutral on Intercept Pharmaceuticals, Raises Price Target to \$140

Financial news for ICPT dated on 2019-02-21: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Feb. 21, 2019

Financial news for ICPT dated on 2019-02-21: 75 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-02-20: Adam Feuerstein of Stat News Tweets on Intercept Pharma

Financial news for ICPT dated on 2019-02-20: 7 Biggest Price Target Changes For Wednesday

Financial news for ICPT dated on 2019-02-20: 71 Biggest Movers From Yesterday

Financial news for ICPT dated on 2019-02-19: Wedbush Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target From \$220 To \$248

Financial news for ICPT dated on 2019-02-19: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ICPT dated on 2019-02-19: Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial

Financial news for ICPT dated on 2019-02-19: Mid-Morning Market Update: Markets Edge Higher; Walmart Tops Q4 Expectations

Financial news for ICPT dated on 2019-02-19: Intercept Pharmaceuticals shares are trading higher after the company reported its Phase 3 REGENERATE study of obeticholic acid patients with NASH-related liver fibrosis met its primary endpoint.

Financial news for ICPT dated on 2019-02-19: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ICPT dated on 2019-02-19: Intercept Pharmaceuticals Reports Pivotal Phase 3 REGENERATE Study Of Obeticholic Acid Patients With NASH-Related Liver Fibrosis Met Primary Endpoint

Financial news for ICPT dated on 2019-02-13: Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure

Financial news for ICPT dated on 2019-02-12: Intercept Pharmaceuticals shares are trading down after Gilead's disappointing NASH trial results; Intercept is also developing a NASH candidate and may be trading down in sympathy with Gilead.

Financial news for ICPT dated on 2019-02-12: Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

Financial news for ICPT dated on 2019-02-12: Gilead's Failed NASH Drug Trial Drags Stock Lower

Financial news for ICPT dated on 2019-02-04: Intercept Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy.

Financial news for ICPT dated on 2019-02-04: Benzinga's Top Upgrades, Downgrades For February 4, 2019

Financial news for ICPT dated on 2019-02-04: Raymond James Upgrades Intercept Pharmaceuticals to Strong Buy

Financial news for ICPT dated on 2019-01-31: Benzinga's Top Upgrades, Downgrades For January 31, 2019

Financial news for ICPT dated on 2019-01-31: Credit Suisse Initiates Coverage On Intercept Pharmaceuticals with Outperform Rating, Announces \$167 Price Target

Financial news for ICPT dated on 2019-01-30: JMP Upgrades Intercept Pharma Ahead Of NASH Trial Data

Financial news for ICPT dated on 2019-01-30: Benzinga's Top Upgrades, Downgrades For January 30, 2019

Financial news for ICPT dated on 2019-01-30: JMP Securities Upgrades Intercept Pharmaceuticals to Market Outperform, Announces \$175 Price Target

Financial news for ICPT dated on 2019-01-24: Needham Upgrades Intercept Pharmaceuticals to Buy, Announces \$150 Price Target

Financial news for ICPT dated on 2019-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2019

Financial news for ICPT dated on 2019-01-23: UBS Initiates Coverage On Intercept Pharmaceuticals with Buy Rating

Financial news for ICPT dated on 2019-01-22: Intercept Pharmaceuticals Option Alert: Mar 15 \$150 Calls at the Ask: 750 @ \$9.6 vs 558 OI; Earnings 2/13 Before Open [est] Ref=\$112.97

Financial news for ICPT dated on 2019-01-18: Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year

Financial news for ICPT dated on 2019-01-14: Laidlaw & Co. Upgrades Intercept Pharmaceuticals to Buy, Raises Price Target to \$130

Financial news for ICPT dated on 2019-01-07: Intercept Pharma Says it Expects To Read-Out Top-Line Data From the Interim Analysis of its Phase 3 REGENERATE Trial in Q1 2019, Plans to Complete Enrollment of its Phase 3 REVERSE Trial in 2019

Financial news for ICPT dated on 2018-12-20: Raymond James: Gilead In NASH For The Long Haul

Financial news for ICPT dated on 2018-12-13: Intercept Pharmaceuticals Option Alert: Jan, 2020 \$70 Calls Sweep (4) near the Ask: 525 @ \$57.0 vs 547 OI; Ref=\$112.73

Financial news for ICPT dated on 2018-12-12: Benzinga's Top Upgrades, Downgrades For December 12, 2018

Financial news for ICPT dated on 2018-12-12: B. Riley FBR Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces \$155 Price Target

Financial news for ICPT dated on 2018-11-19: Oppenheimer Upgrades Intercept Pharmaceuticals to Outperform, Announces \$140 Price Target

Financial news for ICPT dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for ICPT dated on 2018-10-31: Intercept Reaffirms FY18 Ocaliva Sales \$170M-\$185M

Financial news for ICPT dated on 2018-10-31: Intercept Pharmaceuticals Reaffirms FY18 Octavia Net Sales Guidance Of \$170M-\$185M

Financial news for ICPT dated on 2018-10-31: Intercept Q3 EPS \$(2.18) Beats \$(2.55) Estimate, Sales \$46.986M Miss \$48.46M Estimate

Financial news for ICPT dated on 2018-10-03: 45 Biggest Movers From Yesterday

Financial news for ICPT dated on 2018-10-02: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ICPT dated on 2018-10-02: 10 Biggest Price Target Changes For Tuesday

Financial news for ICPT dated on 2018-10-02: Benzinga's Top Upgrades, Downgrades For October 2, 2018

Financial news for ICPT dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for ICPT dated on 2018-10-02: Raymond James Downgrades Intercept Pharmaceuticals to Outperform, Raises Price Target to \$141

Financial news for ICPT dated on 2018-10-01: Cantor Fitzgerald Assumes Intercept Pharmaceuticals at Overweight, Announces \$170 Price Target

Financial news for ICPT dated on 2018-09-28: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results

Financial news for ICPT dated on 2018-09-21: Intercept Pharmaceuticals Option Alert: Dec 21 \$120 Calls Sweep (200) near the Bid: 563 @ \$14.501 vs 1252 OI; Earnings 10/31 Before Open [est] Ref=\$116.8732

Financial news for ICPT dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for ICPT dated on 2018-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2018

Financial news for ICPT dated on 2018-09-12: Roth Capital Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces \$192 Price Target

Financial news for ICPT dated on 2018-08-16: 60 Biggest Movers From Yesterday

Financial news for ICPT dated on 2018-08-15: RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data

Financial news for ICPT dated on 2018-08-15: 55 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ICPT dated on 2018-08-15: Benzinga's Top Upgrades, Downgrades For

August 15, 2018

Financial news for ICPT dated on 2018-08-15: RBC Capital Downgrades Intercept Pharmaceuticals to Sector Perform

Financial news for ICPT dated on 2018-08-07: Hearing RBC Says Earlier Reports Of Intercept's Ocaliva Deaths Reported In AERS Is In Line With Historicals, Says There's No Need For Concern

Financial news for ICPT dated on 2018-08-07: 52 Biggest Movers From Yesterday

Financial news for ICPT dated on 2018-08-06: Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

Financial news for ICPT dated on 2018-08-06: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ICPT dated on 2018-08-06: 10 Biggest Price Target Changes For Monday

Financial news for ICPT dated on 2018-08-06: Benzinga's Top Upgrades, Downgrades For August 6, 2018

Financial news for ICPT dated on 2018-08-06: Intercept Pharmaceuticals shares are up 6.2% premarket following bullish analyst activity Monday morning; Wedbush raised price target from \$203-\$217 and Goldman Sachs upgraded the stock from "Sell" to "Buy".

Financial news for ICPT dated on 2018-08-06: Goldman Sachs Upgrades Intercept Pharmaceuticals From Sell To Buy, Announces \$157 Price Target

Financial news for ICPT dated on 2018-08-06: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for ICPT dated on 2018-08-06: Wedbush Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to \$217

Financial news for ICPT dated on 2018-08-03: Laidlaw & Co. Downgrades Intercept Pharmaceuticals to Hold, Raises Price Target to \$95

Financial news for ICPT dated on 2018-08-02: Intercept Pharmaceuticals Q2 EPS \$(2.58) Beats \$(2.84) Estimate, Sales \$43.58M Beat \$41.19M Estimate

Financial news for ICPT dated on 2018-06-28: Benzinga's Top Upgrades, Downgrades For June 28, 2018

Financial news for ICPT dated on 2018-06-28: Raymond James Initiates Coverage On Intercept Pharmaceuticals with Strong Buy Rating, Announces \$122 Price Target

Financial news for ICPT dated on 2018-06-13: Viking Therapeutics Shares Spike ~4%, Intercept Pharma Shares Spike ~1.8% Following Report Madrigal Pharma Is Considering Sale

Financial news for ICPT dated on 2018-06-08: Intercept Pharma Shares Up 3.2%; Traders Circulating Word Bristol-Myers Could Be Interested In NASH Space

Financial news for ICPT dated on 2018-06-07: 27 Stocks Moving In Thursday's Pre-Market Session

Financial news for ICPT dated on 2018-05-08: Intercept Pharmaceuticals Sees FY2018 Ocaliva Sales \$170.0M-185.0M vs \$188.20M Est

Financial news for ICPT dated on 2018-05-08: Intercept Pharmaceuticals Q1 EPS \$(3.22) Beats \$(3.42) Estimate, Sales \$35.963M Miss \$38.94M Estimate

Financial news for ICPT dated on 2018-04-17: 7 Biggest Price Target Changes For Tuesday

Financial news for ICPT dated on 2018-04-17: Wedbush Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to \$203.00

Financial news for ICPT dated on 2018-04-15: Insider Buys Of The Week: Intercept Pharmaceuticals, Macy's And More

Financial news for ICPT dated on 2018-04-13: UPDATE: Intercept Offers Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid's Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Financial news for ICPT dated on 2018-04-13: Intercept Pharma Reports Liver Biopsy



Data From POISE Phase 3 Substudy: '11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with OCA'

Financial news for ICPT dated on 2018-04-10: Form 4 Filing Late Monday Showed Intercept Pharma Director Daniel Bradbury Bought 7.812K Shares at \$64

Financial news for ICPT dated on 2018-04-09: Intercept Pharmaceuticals CEO Mark Pruzanski Buys 7,812 @ Avg Price: \$64.00

Financial news for ICPT dated on 2018-04-06: 34 Biggest Movers From Yesterday

Financial news for ICPT dated on 2018-04-05: 28 Stocks Moving In Thursday's Mid-Day Session

Financial news for ICPT dated on 2018-04-05: Intercept Option Alert: May 18 \$60 Puts at the Bid: 712 @ \$1.95 vs 24 OI; Earnings 5/3 Before Open [est] Ref=\$69.36

Financial news for ICPT dated on 2018-04-05: Intercept Pharmaceuticals Prices 2.34M Upsized Offering At \$64/Share

Financial news for ICPT dated on 2018-04-05: Benzinga Pro's 5 Stocks To Watch Today

Financial news for ICPT dated on 2018-04-05: Intercept Pharma 8-K Late Wed. Night Showed Expectation For FY18 Total Ocaliva Prescriptions Filled To Be Consistent With FY17 Sales; Q1 Sales Expected To Be Slightly Lower Than Q1'17

Financial news for ICPT dated on 2018-04-05: 8 Stocks To Watch For April 5, 2018

Financial news for ICPT dated on 2018-04-04: Intercept Pharmaceuticals Announces \$120M Offering Common Stock, \$92M Private Placement Common Stock

Financial news for ICPT dated on 2018-03-26: UPDATE: Intercept Pharma Filing Shows No Terms Of Settlement, Includes Ruling Remains Subject To Appeal

Financial news for ICPT dated on 2018-03-26: Intercept Pharma 8-K Shows New York Supreme Court Granted Defendants' Motion To Dismiss With Prejudice Derivative Suit Purportedly Brought On Behalf Co.

Financial news for ICPT dated on 2018-03-09: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for ICPT dated on 2018-02-16: Intercept Pharma Says on Feb 13, Co, Sumitomo Dainippon Pharma Entered Into Amendment to Certain License Agreement Dated as of March 29, 2011 -8K

Financial news for ICPT dated on 2018-02-15: BMO Capital Maintains Outperform on Intercept Pharmaceuticals Inc, Raises price target to \$155.00

Financial news for ICPT dated on 2018-02-14: Intercept Pharmaceuticals Reports Q4 EPS \$(4.43) vs \$(3.55) Est., Sales \$37.68M vs \$39M Est.

Financial news for ICPT dated on 2018-02-12: Intercept Reports Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis

Financial news for ICPT dated on 2018-02-12: Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis

Financial news for ICPT dated on 2018-02-07: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ICPT dated on 2018-02-01: Intercept Announces Updated U.S. Prescribing Information for Ocaliva, Says Hepatic Decompensation And Failure Have Been Reported In Patients With Advanced Cirrhosis When Ocaliva Was Dosed More Frequently Than Recommended Starting Dosage

Financial news for ICPT dated on 2018-02-01: Intercept Pharma Shares Moving Higher Premarket As Traders Circulating FDA.gov Alert 'adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease'

Financial news for ICPT dated on 2018-01-02: Hearing Intercept Pharma's Ocaliva Defended At Deutsche Bank, Unconfirmed

Financial news for ICPT dated on 2018-01-02: Intercept Option Alert: Jan 19 \$55 Puts Sweep (38) at the Bid: 715 @ \$1.55 vs 326 OI; Ref=\$58.66

Financial news for ICPT dated on 2017-12-28: Intercept Pharma 8-K Shows Co. Is 'shifting guidance for an announcement of the Phase 3 REVERSE trial in NASH patients with compensated cirrhosis from YE17 to 1Q18'

Financial news for ICPT dated on 2017-12-13: Deutsche Bank Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces \$106.00 Price Target

Financial news for ICPT dated on 2017-11-02: Benzinga's Top Upgrades, Downgrades For November 2, 2017

Financial news for ICPT dated on 2017-11-02: Cantor Fitzgerald Upgrades Intercept Pharmaceuticals to Neutral

Financial news for ICPT dated on 2017-11-01: Laidlaw & Co. Upgrades Intercept Pharmaceuticals to Buy

Financial news for ICPT dated on 2017-11-01: Hearing Laidlaw Upgrades Shares Of Intercept Pharma From Hold To Buy

Financial news for ICPT dated on 2017-11-01: Intercept Pharma Reports Q3 EPS \$(2.89) vs \$(3.38) Est., Sales \$41.334M vs \$37M Est.

Financial news for ICPT dated on 2017-10-25: Benzinga's Option Alert Recap From October 25

Financial news for ICPT dated on 2017-10-25: Inrtercept Option Alert: Dec 15 \$65 Calls Sweep (3) at the Bid: 1100 @ \$4.201 vs 124 OI; Ref=\$60.55

Financial news for ICPT dated on 2017-10-23: Intercept Reports OCA Phase 2AESOP Trial Met Primary Endpoint Of ALP Reduction At 24 Weeks

Financial news for ICPT dated on 2017-10-09: Benzinga's Option Alert Recap From October 9

Financial news for ICPT dated on 2017-10-09: Intercept Option Alert: Oct 20 \$80 Calls Sweep (2) at the Bid: 950 @ \$0.801 vs 563 OI; Ref=\$69.8

Financial news for ICPT dated on 2017-10-06: 15 Biggest Mid-Day Losers For Friday

Financial news for ICPT dated on 2017-10-06: Seaport Global Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces \$136.00 Price Target

Financial news for ICPT dated on 2017-10-04: Benzinga's Top Upgrades, Downgrades For October 4, 2017

Financial news for ICPT dated on 2017-10-04: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ICPT dated on 2017-10-04: JMP Securities Downgrades Intercept Pharmaceuticals to Market Perform

Financial news for ICPT dated on 2017-09-29: Adam Feuerstein Tweets: Trying again: Best performers in Q3: \$DMTX \$MRNS \$MYOK Worst: \$OTIC \$AXON \$ICPT

Financial news for ICPT dated on 2017-09-29: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for ICPT dated on 2017-09-25: Adam Feuerstein Tweets: Doctor invited to speak on \$ICPT call making very impassioned defense of Ocaliva in PBC. He should disclose his financial conflicts, if any.

Financial news for ICPT dated on 2017-09-25: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for ICPT dated on 2017-09-25: Intercept Statement Regarding Ocaliva Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients, Says Patients Were Prescribed 7 Times Higher Than Weekly Recommended Doses; Intercept And FDA Issued Safety Communication To Reinforce Label Dosing

Financial news for ICPT dated on 2017-09-22: Oppenheimer Downgrades Intercept Pharmaceuticals to Perform

Financial news for ICPT dated on 2017-09-22: 12 Biggest Mid-Day Losers For Friday

Financial news for ICPT dated on 2017-09-22: 5 Biggest Price Target Changes For Friday

Financial news for ICPT dated on 2017-09-22: Mid-Day Market Update: Revolution Lighting Technologies Drops Following Reduced FY2017 Outlook; Ascendis Pharma Shares Surge

Financial news for ICPT dated on 2017-09-22: FDA Letter On Intercept Pharma Doesn't

Include Black Box Warning Label...Yet

Financial news for ICPT dated on 2017-09-22: Will Intercept Stock Potential Be Blindsided By FDA Letter?

Financial news for ICPT dated on 2017-09-22: Intercept Pharma Shares Continuing Lower Fri. Following 26% Decline Thurs. Amid Report Of An FDA Warning Letter; Stock Down 13.6% Just After Open; Citi Downgraded Stock To Neutral Earlier

Financial news for ICPT dated on 2017-09-22: Citigroup Downgrades Intercept Pharmaceuticals to Neutral

Financial news for ICPT dated on 2017-09-22: FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades

Financial news for ICPT dated on 2017-09-21: Wells Fargo Downgrades Intercept Pharmaceuticals to Market Perform

Financial news for ICPT dated on 2017-09-21: Adam Feuerstein Tweets: At this point, \$ICPT is probably asking the sell side to STOP defending them. It's only making the situation worse.

Financial news for ICPT dated on 2017-09-21: Adam Feuerstein Tweets: \$ICPT -- Leerink notes FDA hasn't tagged Ocaliva with a black box -- yet -- but don't be surprised if it happens.

Financial news for ICPT dated on 2017-09-21: Intercept Pharma Shares Up \$4+ From Session Lows; Hearing Jefferies Issued Mid-Day Commentary Defending Stock

Financial news for ICPT dated on 2017-09-21: Intercept Pharma Shares Down 3.5% From Session Highs As Traders, Over Last Few Mins., Circulate Chatroom Chatter FDA Sent Warning Letter Related To Liver Treatment

Financial news for ICPT dated on 2017-09-21: Jim Cramer Advises His Viewers On STMicroelectronics, Altria Group And More

Financial news for ICPT dated on 2017-09-15: 18 Biggest Mid-Day Gainers For Friday

Financial news for ICPT dated on 2017-09-15: Benzinga's Top Upgrades, Downgrades For September 15, 2017

Financial news for ICPT dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for ICPT dated on 2017-09-14: RBC Initiates Coverage on 6 Pharma Stocks After Hours

Financial news for ICPT dated on 2017-09-12: 10 Biggest Mid-Day Losers For Thursday

Financial news for ICPT dated on 2017-09-12: Did Improper Practices Affect Growth Trends For Intercept Pharma's Drugs?

Financial news for ICPT dated on 2017-09-12: UPDATE: Cantor Analyst On Intercept Says '...recent growth trends of the drug could have been affected by these improper practices with yet unquantifiable impact on future sales'

Financial news for ICPT dated on 2017-09-12: UPDATE: Cantor Says Events Raised In Intercept's Letter 'signal a potential hurdle for further penetration and/or adoption of the treatment'

Financial news for ICPT dated on 2017-09-12: Cantor Fitzgerald Issues Mid-Day Note On Intercept Pharma, Says Co.'s 'Dear Health Care Provider' Letter Raises Caution On PBC Franchise's Future Growth Potential In More Severe Patients

Financial news for ICPT dated on 2017-09-12: Some Traders Attributing Move Lower In Intercept Pharma To Doc From Co.'s Chief Medical Officer To Health Care Providers Highlighting Seemingly Negative Postmarketing Cases For Its OCALIVA; However, Doc Is Dated Sept. 8, 2017

Financial news for ICPT dated on 2017-09-12: Morgan Stanley Healthcare Conference Continues Today, Presenters Include: Inoviva, Seattle Genetics, Lab Corp, Anthem, Juno Therapeutics, and Intercept Pharmaceuticals

Financial news for ICPT dated on 2017-09-12: BZ NOTE On Downside In Intercept Pharma Shares: Exec From Co. Will Be Speaking At Morgan Stanley's Healthcare Conference At 11:45 a.m. EDT

Financial news for ICPT dated on 2017-09-12: Intercept Pharma Shares Indicated Down ~12% Premarket On No News

Financial news for ICPT dated on 2017-08-03: Intercept Pharma Shares Bounce ~4% Off Session Lows; Stock Down Nearly 20% Since Jul. 28, Has High Short Interest At ~30%; Not Seeing Any News Thurs.

Financial news for ICPT dated on 2017-08-03: Intercept Pharma Spikes to High of \$109.50 on Volume

Financial news for ICPT dated on 2017-07-31: Intercept Pharma Analysts See Growth Ahead, But Keep Underweight Rating For Now

Financial news for ICPT dated on 2017-07-31: 15 Biggest Mid-Day Losers For Monday

Financial news for ICPT dated on 2017-07-31: Mid-Morning Market Update: Markets Mostly Higher; Discovery Communications To Acquire Scripps Networks Interactive

Financial news for ICPT dated on 2017-07-31: Intercept Pharmaceuticals Announces The CONTROL Trial Met primary Objective By Showing Newly Started Treatment With atrovastatin Rapidly Reversed OCA-Associated Increases In LDL To Below Baseline Levels

Financial news for ICPT dated on 2017-07-31: Intercept Reports Phase 2 AESOP OCA Met Primary Endpoint Of ALP Reduction At 24 Weeks

Financial news for ICPT dated on 2017-07-31: Intercept Pharma Q2 EPS \$(3.46) vs \$(3.64) Est., Sales \$30.89M vs \$27.49M Est.

Financial news for ICPT dated on 2017-07-11: Intercept Pharma Shares Up 4.1% Following Jefferies Initiation With Buy Rating, \$275 Price Target

Financial news for ICPT dated on 2017-07-11: Jefferies Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces \$275.00 Price Target

Financial news for ICPT dated on 2017-06-27: Companies Holding Shareholder Meetings Today Include Autohome, Gamestop, Mastercard, Kyocera, Intercept Pharma, PNC Financial, pSivida, ReWalk Robotics, RH, SITO Mobile, and Synergy Pharmaceuticals

Financial news for ICPT dated on 2017-06-12: Intercept Gives Update on Data from FLINT Trial

Financial news for ICPT dated on 2017-05-25: Intercept Pharma Reports Health Canada Has Granted Approval for Ocaliva for Treatment of PBC

Financial news for ICPT dated on 2017-05-04: Intercept Pharma Earlier Reported Q1 EPS \$(3.61) vs \$(4.25) Est, Sales \$21.05M vs \$15.80M Est

Financial news for ICPT dated on 2017-05-04: TheStreet's Adam Feuerstein Tweets '\$ICPT completed enrollment in the interim analysis cohort of the OCA ph3 NASH trial. Data 1H 2019.'

Financial news for ICPT dated on 2017-04-04: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ICPT dated on 2017-03-02: NICE Recommends Ocaliva for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland -

Financial news for ICPT dated on 2017-02-23: Intercept Pharmaceuticals Reports Q4 EPS \$(4.84) vs. \$(3.74) Est., Sales \$13.8M vs. \$8.96M Est.

Financial news for ICPT dated on 2017-02-13: Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints

Financial news for ICPT dated on 2017-02-10: What's With Wall Street's Lofty Price Targets On Intercept?

Financial news for ICPT dated on 2017-02-10: Cantor Fitzgerald In Midday Note Out Negative On Intercept, Maintains Underweight Rating Seeing No Change To Probability Of Success For Lead Candidate OCA In Current Phase 3 Trial

Financial news for ICPT dated on 2017-02-10: Here's Why Shares Of Intercept Jumped Nearly 10% On Friday

Financial news for ICPT dated on 2017-02-10: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for ICPT dated on 2017-02-10: Adam Feuerstein Tweets: \$ICPT says all changes to OCA ph3 study design accelerate enrollment/time to data and make positive results more likely.

Financial news for ICPT dated on 2017-02-10: UPDATE: Intercept Primary Endpoint Amended For Phase 3 REGENERATE Trial

Financial news for ICPT dated on 2017-02-10: Intercept Spikes to Premarket High of \$123

Financial news for ICPT dated on 2017-02-10: Intercept Shares Spike To High Of \$123, Now Trading At \$118

Financial news for ICPT dated on 2017-02-10: Adam Feuerstein Tweets: \$ICPT amending ph3 study of OCA in NASH.

Financial news for ICPT dated on 2017-02-10: Intercept Shares Down Premarket, As Company Will Give An Update On Phase 3 REGENERATE Trial Obeticholic Acid For NASH Patients With Liver Fibrosis At 8:30am ET

Financial news for ICPT dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for ICPT dated on 2017-02-07: Carmignac Gestion Reports 8.2% Stake In Intercept Pharmaceutical

Financial news for ICPT dated on 2017-01-27: Hearing Takeover Chatter In Intercept

Financial news for ICPT dated on 2017-01-20: 15 Biggest Mid-Day Losers For Friday

Financial news for ICPT dated on 2017-01-20: Benzinga's Top Upgrades, Downgrades For January 20, 2017

Financial news for ICPT dated on 2017-01-20: Needham Downgrades Intercept Pharmaceuticals To Hold

Financial news for ICPT dated on 2017-01-05: Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Financial news for ICPT dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for ICPT dated on 2016-12-29: Why Companies File SEC CTO Requests

Financial news for ICPT dated on 2016-12-29: Wall Street's M&A Chatter From December 28

Financial news for ICPT dated on 2016-12-28: Intercept Shares Higher After It Requests To Keep Piece Of Q3 Info Secret Until 2020

Financial news for ICPT dated on 2016-12-28: Intercept Pharmaceuticals On Buyout Chatter Related To Recent Filing Of Confidential Treatment Order Tells Benzinga It Does Not Comment On M&A Speculation

Financial news for ICPT dated on 2016-12-28: Intercept Pharma Shares Spike to Session Highs, Quickly Give Back Gains from Last Few Mins as Traders Show Skepticism on Unconfirmed Takeover Chatter Being Passed Around

Financial news for ICPT dated on 2016-12-28: Intercept Spikes to High of \$112.90 on Volume

Financial news for ICPT dated on 2016-12-28: Shares of Intercept Pharmaceuticals Up 4% At \$108.06/Share

Financial news for ICPT dated on 2016-12-14: BMO Capital Healthcare Conf. Takes Place Today; Presenters Include Neurocrine Biosciences, Ionis Pharmaceuticals, Horizon Pharma, And Intercept Pharmaceuticals

Financial news for ICPT dated on 2016-12-14: Intercept Gets Marketing Authorization From the European Commission for Ocaliva

Financial news for ICPT dated on 2016-12-05: Traders Attributing Recent Spike Higher in Intercept Shares to Bloomberg Report Genfit is Exploring Options, Including a Possible Sale

Financial news for ICPT dated on 2016-11-11: Intercept Highlights Ocaliva Poster for AASLD: Presentations to 'explore changes in biochemical markers of disease progression in PBC patients with cirrhosis and renal impairment'

Financial news for ICPT dated on 2016-11-03: Intercept Pharma Shares Edge Off Session Lows, Still Down 13% for Session; Hearing Baird Has Issued Mid-Day Defense on Name, Reiterated \$332 Price Target

Financial news for ICPT dated on 2016-11-03: Intercept Pharmaceuticals Reports Q3 EPS \$(3.59) vs. Est. \$(3.82), Rev. \$5.1M vs. Est. \$4.7M

Financial news for ICPT dated on 2016-10-14: Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva for the Treatment of Primary Biliary Cholangitis in the European Union

Financial news for ICPT dated on 2016-10-14: EMA Issues Conditional Marketing Approval Recommendation for Intercept's Ocaliva for Treatment of Biliary Cirrhosis

Financial news for ICPT dated on 2016-10-06: Option Alert: ICPT Oct \$165 Call Sweep; 537 @Ask @\$2.20

Financial news for ICPT dated on 2016-09-20: NASH Sympathy Plays On Tobira Therapeutics Deal

Financial news for ICPT dated on 2016-09-20: Conatus Pharma Shares Trading Up 27% on the Heels of Deal for Tobira Therapeutics; Also Watching Galmed Pharma, Galectin Therapeutics, Enanta Pharma, Intercept

Financial news for ICPT dated on 2016-09-19: Intercept Pharma Files NDA to Health Canada for Obeticholic Acid

Financial news for ICPT dated on 2016-09-12: Intercept Announces Final Approval of Settlement of Class Action Litigation; Intercept to Pay \$55M -8-K

Financial news for ICPT dated on 2016-08-04: Thursday Morning's Top Earnings Reports

Financial news for ICPT dated on 2016-08-04: Intercept Pharmaceuticals Reports Q2 EPS \$(3.14) vs. Est. \$(3.70), Rev. \$5.5M vs. Est. \$1.46M

Financial news for ICPT dated on 2016-07-06: Intercept Shares Turn Negative Following Mid-Day Sell Rating From Cantor

Financial news for ICPT dated on 2016-07-06: Intercept Shares Falling as Hearing Cantor Fitzgerald Issued Mid-Day New Sell Rating, \$58 Price Target on Stock

Financial news for ICPT dated on 2016-06-30: 10 Biggest Mid-Day Losers For Thursday

Financial news for ICPT dated on 2016-06-30: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for ICPT dated on 2016-06-29: Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes

Financial news for ICPT dated on 2016-06-28: Intercept Pharmaceuticals Finds Resistance

Financial news for ICPT dated on 2016-06-17: Intercept Pharmaceuticals Set To Rebound, Vetr Crowd Says

Financial news for ICPT dated on 2016-06-01: Here's Why Barclays Is Bullish On Intercept Pharma

Financial news for ICPT dated on 2016-05-31: Credit Suisse Reiterates Intercept's Lofty \$200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'

Financial news for ICPT dated on 2016-05-31: Credit Suisse On Intercept Pharma: 'We don't expect much competition for patients from ongoing placebo controlled COBALT trial'

Financial news for ICPT dated on 2016-05-31: Cowen Lifts Intercept's Price Target To \$215 Following Ocaliva Approval

Financial news for ICPT dated on 2016-05-31: Wild Ride For Intercept Pharmaceutical Investors

Financial news for ICPT dated on 2016-05-31: Today's Top 10 Pre-Market Gainers

Financial news for ICPT dated on 2016-05-31: 3 Reasons Goldman Sachs Still Neutral On Intercept Pharma

Financial news for ICPT dated on 2016-05-31: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ICPT dated on 2016-05-31: Intercept's Ocaliva To Experience 'Sluggish Uptake,' Investment Thesis Now 'Rapidly Shifts' To Execution In PBC

Financial news for ICPT dated on 2016-05-31: Intercept +13.5% Premarket @\$161.03; FCC Granted Accelerated Approval to Ocaliva for Treatment of Patients with PBC

Financial news for ICPT dated on 2016-05-29: Intercept Pharmaceuticals Announced FDA Grants Accelerated Approval to Ocaliva for the Treatment of Patients with PBC

Financial news for ICPT dated on 2016-05-18: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016, May 21-24

Financial news for ICPT dated on 2016-05-05: Intercept Pharma Reports Q1 EPS \$(5.17) vs \$(3.60) Est., Licensing Sales \$445K vs \$860K Est.

Financial news for ICPT dated on 2016-05-03: UPDATE: Lawsuit Claimed Intercept and Certain Officers Made Material Misrepresentations, Omissions Regarding Early Stopping of Phase 2b FLINT Trial of Obeticholic Acid in NASH

Financial news for ICPT dated on 2016-05-03: Intercept Pharmaceuticals Announces Agreement With Lead Plaintiff to Seek Court Approval of Proposed Resolution of Pending Class Action Litigation

Financial news for ICPT dated on 2016-04-08: Another Wild Ride In Intercept Pharmaceuticals

Financial news for ICPT dated on 2016-04-08: Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To \$80

Financial news for ICPT dated on 2016-04-08: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for ICPT dated on 2016-04-08: Intercept Jumps 5%, Confirms FDA's Unanimous Decision To Recommend Accelerated Ocaliva Approval

Financial news for ICPT dated on 2016-04-08: Morgan Stanley Downgrades Intercept Pharmaceuticals to Underperform, Lowers PT to \$80.00

Financial news for ICPT dated on 2016-04-07: Intercept Resume Trade, Shares Falling To \$180/Share

Financial news for ICPT dated on 2016-04-07: Shares of Intercept Pharma to Resume Trade at 5:30 p.m. EDT

Financial news for ICPT dated on 2016-04-07: Intercept to Resume Trading at 5:30 PM ET

Financial news for ICPT dated on 2016-04-07: Intercept Publishes FDA Unanimous Decision Of Accelerated Approval Of Ocaliva For PBC Treatment, PDUFA is May 29th, 2016

Financial news for ICPT dated on 2016-04-07: FDA Unanimous Vote Sees Substantial Evidence To Support Accelerated Approval Of Intercept's Liver Drug, Vote Was 17-0

Financial news for ICPT dated on 2016-04-07: The Street's Adam Feuerstein Tweets: FDA webcast of the \$ICPT went dark.

Financial news for ICPT dated on 2016-04-07: The Street's Adam Feuerstein Tweets: FDA biostat just showed K-M curves for OCA data in which agency's analysis is superior to \$ICPT Panel over. Positive vote coming.

Financial news for ICPT dated on 2016-04-07: Many Sell Side Firm Notes In Recent Days Saying They Expect Intercept Pharma's OCA To Be Approved For PBC; Firms Include Leerink, Goldman, and Barclays, Among Others

Financial news for ICPT dated on 2016-04-07: UPDATE: Intercept FDA Panel Begins 8am ET, AdComm To Discuss OCA For Use In PBC; Shares Up 5.6% Pre-Market

Financial news for ICPT dated on 2016-04-07: Intercept Pharma. Shares Halted, Company Has AdComm For Obeticholic Acid (OCA) NDA For Treatment Of Progressive Liver Disease

Financial news for ICPT dated on 2016-04-07: Intercept Pharma Shares Halted News Pending

Financial news for ICPT dated on 2016-04-07: BMO Capital Initiates Coverage on Intercept Pharmaceuticals at Outperform

Financial news for ICPT dated on 2016-04-05: Mid-Afternoon Market Update: Dow Falls Over 100 Points; Valeant Pharmaceuticals Shares Spike Higher

Financial news for ICPT dated on 2016-04-05: Mid-Day Market Update: Intercept Pharmaceuticals Gains Following Release of FDA Advisory Committee Documents; Godaddy

Shares Decline

Financial news for ICPT dated on 2016-04-05: Benzinga's Volume Movers

Financial news for ICPT dated on 2016-04-05: Mid-Morning Market Update: Markets Open Lower; Walgreens Earnings Top Views

Financial news for ICPT dated on 2016-04-05: Benzinga's Top Upgrades

Financial news for ICPT dated on 2016-04-05: Intercept Pharma Investors Cheering FDA Briefing Doc Release

Financial news for ICPT dated on 2016-04-05: Intercept Shares Spike ~\$10 Over Last Few Mins, Now Up ~16%

Financial news for ICPT dated on 2016-04-05: Wells Fargo Upgrades Intercept Pharmaceuticals to Outperform

Financial news for ICPT dated on 2016-04-05: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ICPT dated on 2016-04-05: Intercept Shares Spike to \$145 Premarket Following Release of FDA Advisory Committee Documents

Financial news for ICPT dated on 2016-03-30: Benzinga's Top Initiations

Financial news for ICPT dated on 2016-03-30: Credit Suisse Initiates Intercept With Outperform, \$200 Target

Financial news for ICPT dated on 2016-03-30: Goldman Sachs Initiates Coverage on Intercept Pharmaceuticals at Neutral, Announces \$114.00 PT

Financial news for ICPT dated on 2016-03-30: Credit Suisse Initiates Coverage on Intercept Pharmaceuticals at Outperform, Announces \$200.00 PT

Financial news for ICPT dated on 2016-03-18: Intercept Shares Move to High; Hearing Unconfirmed Market Chatter of Offer from AstraZeneca

Financial news for ICPT dated on 2016-03-16: Intercept to Study Role of Gut Microbiota in Treatment of Non-Viral Liver Diseases by Obeticholic Acid

Financial news for ICPT dated on 2016-03-16: Intercept Pharmaceuticals to Study the Role of Gut Microbiota in the Treatment of Non-Viral Liver Diseases by Obeticholic Acid

Financial news for ICPT dated on 2016-03-09: Roth's Piro: Galectin Therapeutics Shares Can Quadruple In Next 12 Months

Financial news for ICPT dated on 2016-02-24: Barclays Maintains Overweight on Intercept Pharmaceuticals, Lowers PT to \$200.00

Financial news for ICPT dated on 2016-02-23: Intercept Pharma. Reports Q4 EPS \$(3.62) vs. Est. \$(3.15)

Financial news for ICPT dated on 2016-02-16: Keep An Eye On These 7 Stocks For February 16, 2016

Financial news for ICPT dated on 2016-02-15: Benzinga's Weekend M&A Chatter

Financial news for ICPT dated on 2016-02-12: UPDATE: Oppenheimer Says Gilead Or Shire As Buyers Of ICPT Less Likely Than Merck, Abbvie, BMY, Pfizer, AstraZeneca and Roche

Financial news for ICPT dated on 2016-02-12: Oppenheimer Positive On ICPT, Says 'if the biotech gods have even a minor appreciation for irony, ICPT will be acquire'

Financial news for ICPT dated on 2016-02-12: RBC Capital 'fundamentally' Thinks No Deal Could Be In The Near Term For Intercept Pharma

Financial news for ICPT dated on 2016-02-12: Intercept Pharmaceuticals Soars 30%; Reuters Reported Company Exploring A Potential Sale

Financial news for ICPT dated on 2016-02-12: Hearing Wells Fargo Out Negative on Prospects for Intercept Deal Prior to Apr 7 FDA Meeting

Financial news for ICPT dated on 2016-02-12: UPDATE: Intercept Said to be Working With Bankers on Potential Sale

Financial news for ICPT dated on 2016-02-12: Intercept Halted on C/B



Financial news for ICPT dated on 2016-02-12: -Intercept Pharmaceuticals Explores Following Receipt of Interest From Other Companies -Reuters

Financial news for ICPT dated on 2016-02-09: CentreView Partners Said to be Advising on Sale of Intercept to Astrazeneca

Financial news for ICPT dated on 2016-02-02: Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail

Financial news for ICPT dated on 2016-01-29: Intercept Pharma. 8-K Shows CFO Barbara Duncan To Leave Company, Will Begin Search For Successor

Financial news for ICPT dated on 2016-01-29: Benzinga's Top Upgrades

Financial news for ICPT dated on 2016-01-29: Morgan Stanley Upgrades Intercept Pharma, Maintains \$100 Target

Financial news for ICPT dated on 2016-01-29: Morgan Stanley Upgrades Intercept Pharmaceuticals to Equalweight, Maintains \$100.00 PT

Financial news for ICPT dated on 2016-01-29: Morgan Stanley Upgrades Intercept Pharmaceuticals to Equalweight, Maintains \$100.00 PT

Financial news for ICPT dated on 2016-01-11: Ameriprise Financial Reports 11.77% Passive Stake In Intercept Pharmaceuticals

Financial news for ICPT dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for ICPT dated on 2015-12-21: UPDATE: Intercept Pharma Shares Jump 4.3+% Midday, Now In Positive Territory at ~\$162.80

Financial news for ICPT dated on 2015-12-21: Intercept Spikes Higher

Financial news for ICPT dated on 2015-12-18: Intercept Pharma Shares Trading Down ~8% Following News Late Thurs. Afternoon the FDA Has Extended the Date for Panel Review for Co.'s Treatment of PBC

Financial news for ICPT dated on 2015-12-15: Mid-Afternoon Market Update: Dow Surges Over 200 Points; Intercept Pharma Shares Climb On Takeover Rumor

Financial news for ICPT dated on 2015-12-15: Intercept Pharma Higher On Takeover Rumor

Financial news for ICPT dated on 2015-12-15: Mid-Day Market Update: Kennametal Drops On Lowered Guidance; Lumber Liquidators Shares Jump

Financial news for ICPT dated on 2015-12-15: Mid-Morning Market Update: Markets Open Higher; FactSet Misses Q1 Views

Financial news for ICPT dated on 2015-12-15: Intercept +9.5% Premarket @\$152.99; 'This is Money' Reported Monday that Shire Could be a Bidder for the Co

Financial news for ICPT dated on 2015-12-08: Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

Financial news for ICPT dated on 2015-12-07: Wedbush's Moussatos Offers Probabilities for Upcoming Catalysts in Emerging Pharma Sector Heading Into '16: Discusses 14 Cos., Including BioMarin, Intercept, Regulus, Relypsa, Vitae, Xoma

Financial news for ICPT dated on 2015-12-07: Intercept Reports Initiation of Prospective Trial to Explore Effect of Combined OCA, Statin Therapy on Lipid Metabolism in NASH Patients

Financial news for ICPT dated on 2015-12-04: Wells Fargo Initiates Coverage on Intercept Pharmaceuticals at Market Perform

Financial news for ICPT dated on 2015-11-30: Intercept Pharmaceuticals Begins Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist

Financial news for ICPT dated on 2015-11-15: Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015

Financial news for ICPT dated on 2015-11-15: Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015

Financial news for ICPT dated on 2015-11-10: Benzinga's M&A Chatter for Tuesday November 10, 2015

Financial news for ICPT dated on 2015-11-10: Strength in Intercept May be Attributed to Morgan Stanley Note Mentioning It as Potential Takeover Target for Amgen

Financial news for ICPT dated on 2015-11-10: Intercept Pharmaceuticals Spiking Higher

Financial news for ICPT dated on 2015-11-09: Intercept Pharmaceuticals Reports Q3 EPS \$(2.10) vs. Est. \$(2.74), Rev. \$445K vs. Est. \$420K

Financial news for ICPT dated on 2015-10-29: Morgan Stanley Sees 33% Downside At Intercept Pharma, Increased Risk

Financial news for ICPT dated on 2015-10-28: Intercept Pharmaceuticals Rebounds After Phase 2 Trial Of OCA Disappoints

Financial news for ICPT dated on 2015-10-28: Mid-Morning Market Update: Markets Open Higher; Hershey Earnings Beat Views

Financial news for ICPT dated on 2015-10-28: Morning Market Losers

Financial news for ICPT dated on 2015-10-28: Intercept Pharmaceuticals Announces Results Of Phase 2 Trial Of OCA In Nash Patients In Japan; Says 40MG OCA Dose Group Achieved Statistical Significance On The Primary Endpoint vs Placebo

Financial news for ICPT dated on 2015-09-28: Intercept Pharma Reports Initiation of REGENERATE Trial for Obeticholic Acid in NASH Patients with Advanced Liver Fibrosis

Financial news for ICPT dated on 2015-08-31: Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For \$6/Share

Financial news for ICPT dated on 2015-08-31: Morning Market Gainers

Financial news for ICPT dated on 2015-08-31: Intercept +4.5% Premarket Following Announcement of FDA Priority Review for Obeticholic Acid for Treatment of Primary Biliary Cirrhosis

Financial news for ICPT dated on 2015-08-31: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

Financial news for ICPT dated on 2015-08-13: Calls Of Note: Wall Street Research Moving The Market On Thursday

Financial news for ICPT dated on 2015-08-10: Pipeline Updates Make These Three Biotech Stocks Worth Watching

Financial news for ICPT dated on 2015-08-05: Intercept Pharma Reports Q2 Loss of \$1.99/Share

Financial news for ICPT dated on 2015-07-10: CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton

Financial news for ICPT dated on 2015-07-06: How Wedbush's Liana Moussatos Is Trading These Biopharma Stocks

Financial news for ICPT dated on 2015-06-30: 5 Biotech Stocks On Deck With The FDA

Financial news for ICPT dated on 2015-06-29: Intercept Pharma Announces Submission of Application in US and Europe to Market Biliary Cirrhosis Treatment

Financial news for ICPT dated on 2015-06-16: Sportsman's Warehouse, Bob Evans, Peabody Energy Lead Tuesday's After-Hours Movers

Financial news for ICPT dated on 2015-05-21: Benzinga's Top Initiations

Financial news for ICPT dated on 2015-05-21: 4 SMID-Cap Biotechs Barclays Just Confessed It Loves

Financial news for ICPT dated on 2015-05-21: Barclays Initiates Intercept Pharmaceuticals With Overweight

Financial news for ICPT dated on 2015-05-21: Barclays Initiates Coverage on Intercept Pharmaceuticals at Overweight, Announces \$425.00 PT

Financial news for ICPT dated on 2015-05-20: Intercept Pharmaceuticals Downgraded

Financial news for ICPT dated on 2015-05-19: Bank of America Downgrades Intercept Pharmaceuticals to Neutral

Financial news for ICPT dated on 2015-05-19: Intercept Pharmaceuticals Announces

Plans for Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH

Financial news for ICPT dated on 2015-05-18: Will The Bulls In Options Continue To Be Disappointed This Week?

Financial news for ICPT dated on 2015-05-13: Intercept Pharmaceuticals Breaks Out

Financial news for ICPT dated on 2015-05-12: Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update

Financial news for ICPT dated on 2015-05-11: Intercept Q1 EPS -\$1.78 vs -\$1.69 est

Financial news for ICPT dated on 2015-04-23: Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients

Financial news for ICPT dated on 2015-04-17: Intercept Pharma Shares Higher Following New Buy Rating, \$465 Target From UBS

Financial news for ICPT dated on 2015-04-17: UBS Initiates Coverage on Intercept Pharmaceuticals at Buy, Announces \$465.00 PT

Financial news for ICPT dated on 2015-04-10: Biotech Investors: Nomura Says To Watch These Dates

Financial news for ICPT dated on 2015-04-08: Options Pro Says Intercept Shares Will Go 'Much Higher' Through The End Of The Year

Financial news for ICPT dated on 2015-04-06: Intercept Pharma Reports Proceeds From Public Offering Of \$366.8M

Financial news for ICPT dated on 2015-04-01: Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals

Financial news for ICPT dated on 2015-04-01: CNBC's Stock Pops & Drops From March 31

Financial news for ICPT dated on 2015-03-31: 8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks

Financial news for ICPT dated on 2015-03-31: Morning Market Losers

Financial news for ICPT dated on 2015-03-31: Intercept Prices 1.2M Shares, Proceeds To Be ~\$338.4M

Financial news for ICPT dated on 2015-03-31: Intercept Shares Fall 4% Premarket Following Announcement of 1.2M Share Secondary Offering

Financial news for ICPT dated on 2015-03-31: Intercept Pharmaceuticals Announces Proposed 1.2M Share Offering Of Common Stock

Financial news for ICPT dated on 2015-03-31: Intercept Pharma Prices 1.2M Shares of Common Stock

Financial news for ICPT dated on 2015-03-30: Intercept Pharma Holder Orbimed Reports Stake Of 4.95%, Down From 5.64% On 03/25/2015

Financial news for ICPT dated on 2015-03-30: Intercept Pharmaceuticals Shareholder Orbimed Advisors Sells 157,200 Shares @\$286.75/Share -Form 4

Financial news for ICPT dated on 2015-03-27: Genfit's Loss Is Gain For Intercept Pharmaceuticals

Financial news for ICPT dated on 2015-03-27: Intercept Pharmaceuticals Shares Rise ~4% Premarket as Deutsche Bank Raises PT from \$300 to \$400

Financial news for ICPT dated on 2015-03-26: Genfit Will Target High-Risk Patients In Phase 3 Trial

Financial news for ICPT dated on 2015-03-26: Adam Feuerstein @adamfeuerstein Tweet: \$GNFT is asked to disclose the the uncorrected results for the NASH resolution primary endpoint -- and refuses. Game over.

Financial news for ICPT dated on 2015-03-26: Genfit States LDL Levels "Significantly Decreased"; Positive Cardio-Metabolic Effects in GFT505

Financial news for ICPT dated on 2015-03-26: Genfit GFT505 Phase 3 Trial To Begin By Year End

Financial news for ICPT dated on 2015-03-26: Genfit Conference Call Begins

Financial news for ICPT dated on 2015-03-26: UPDATE: Genfit Shows No Signs Of Cardiac Events, No Signal On Cancer

Financial news for ICPT dated on 2015-03-26: Genfit Announces Topline Results From Golden-505 Trial In Nash; Gft505 Demonstrates Dose-Dependent Efficacy On Primary Endpoint, After Controlling For Baseline Severity And Heterogeneity

Financial news for ICPT dated on 2015-03-26: Intercept Spikes Higher

Financial news for ICPT dated on 2015-03-25: Intercept Pharma Holder Orbimed Cuts Stake From 6.56% To 5.64%

Financial news for ICPT dated on 2015-03-24: Why Intercept Might Be A Better Bet Than Biogen Right Now

Financial news for ICPT dated on 2015-03-23: Janney Capital Maintains Buy on Intercept Pharmaceuticals, Raises PT to \$350.00

Financial news for ICPT dated on 2015-03-20: Morning Market Gainers

Financial news for ICPT dated on 2015-03-20: Biotech Stocks Soar Amid Positive News

Financial news for ICPT dated on 2015-03-20: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2015-03-20: US Stock Futures Signal Higher Start On Wall Street

Financial news for ICPT dated on 2015-03-20: Intercept Shares at \$300 Premarket on Positive Phase 2B Flint Trial Data

Financial news for ICPT dated on 2015-03-20: Intercept Announces Positive Data Analyses from FLINT Trial of Obeticholic Acid in NASH

Financial news for ICPT dated on 2015-03-18: Is Intercept The Next Biotech To Break Out?

Financial news for ICPT dated on 2015-03-18: Baird Maintains Outperform on Intercept Pharmaceuticals, Raises PT to \$344.00

Financial news for ICPT dated on 2015-03-17: Benzinga's Top Initiations

Financial news for ICPT dated on 2015-03-17: MLV & Co. Initiates Intercept Pharmaceuticals With Hold

Financial news for ICPT dated on 2015-03-17: MLV & Co. Initiates Coverage on Intercept Pharmaceuticals at Hold, Announces \$273.00 PT

Financial news for ICPT dated on 2015-03-16: Intercept Pharmaceuticals Revisits \$300 For The First Time In 7 Months

Financial news for ICPT dated on 2015-03-05: Will Intercept Pharma Outperform? These Analysts Think So

Financial news for ICPT dated on 2015-03-04: US Judge Refuses to Dismiss Shareholder Lawsuit vs Intercept Pharmaceuticals Regarding Disclosures Relating to Fliny Trial

Financial news for ICPT dated on 2015-03-04: Intercept Shares +5%; Hearing Data, Possibly Additional News Around March 20-22

Financial news for ICPT dated on 2015-03-02: Intercept Pharmaceuticals Reports Q4 Loss/Share \$(1.63); May Not Compare With \$0.06 EPS Est; Revenue \$445K vs \$430K Est

Financial news for ICPT dated on 2015-03-02: Earning & Economic Calendar for Monday March 2, 2015

Financial news for ICPT dated on 2015-03-02: Earnings Scheduled For March 2, 2015

Financial news for ICPT dated on 2015-02-27: Hearing Unconfirmed Market ChatterEarly FDA Approval to be Announced for Intercept Nash Treatment; March 20-22

Financial news for ICPT dated on 2015-02-23: Intercept to Report FY 2014 Financial Results on March 2, 2015

Financial news for ICPT dated on 2015-02-19: Intercept Appoints Lisa Bright Chief Commercial & Corporate Affairs Officer

Financial news for ICPT dated on 2015-02-04: Intercept Pharma Prices 1M Share Offering at \$176/Share, Expecting Net Proceeds \$166.2M

Financial news for ICPT dated on 2015-02-03: Intercept Pharmaceuticals Announces 800,000 Share Proposed Public Offering of Common Stock

Financial news for ICPT dated on 2015-02-02: Cowen And Company Analyst Explains Why Intercept Pharmaceuticals Is 'Absolutely A Buy'

Financial news for ICPT dated on 2015-02-01: Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching

Financial news for ICPT dated on 2015-02-01: Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical

Financial news for ICPT dated on 2015-01-30: Mid-Afternoon Market Update: Crude Oil Jumps 7.5%; Visa Shares Climb On Earnings Beat

Financial news for ICPT dated on 2015-01-30: Intercept Pharmaceuticals Soars 20%, Possible Short Squeeze

Financial news for ICPT dated on 2015-01-30: Mid-Day Market Update: Amazon Jumps On Upbeat Earnings; Hawaiian Holdings Shares Slide

Financial news for ICPT dated on 2015-01-30: Benzinga's Volume Movers

Financial news for ICPT dated on 2015-01-30: Mid-Morning Market Update: Markets Drop; Mastercard Profit Tops Expectations

Financial news for ICPT dated on 2015-01-30: Morning Market Gainers

Financial news for ICPT dated on 2015-01-30: Friday Morning Movers: Amazon Pops, Deckers Outdoor Plummets Following Earnings Results

Financial news for ICPT dated on 2015-01-30: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2015-01-29: Intercept Receives Breakthrough Therapy Designation from FDA for Obeticholic Acid for NASH With Liver Fibrosis

Financial news for ICPT dated on 2015-01-22: Deutsche Bank: No Big Move In FY15 For Intercept Pharmaceuticals

Financial news for ICPT dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for ICPT dated on 2014-12-15: Bank of America Reinstates Buy on Intercept, Announces \$188.00 PT

Financial news for ICPT dated on 2014-12-05: Intercept Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology

Financial news for ICPT dated on 2014-12-05: Intercept Announces Publication of Meta-Analysis From Global PBC Study Group in Gastroenterology

Financial news for ICPT dated on 2014-12-02: Dan Rosenblum @sharkbiotech Tweet: \$ICPT CEO more confident in OCA for NASH now then back in January when trial was

Financial news for ICPT dated on 2014-11-17: Intercept Pharmaceuticals Names Lisa Bright as Head of Europe

Financial news for ICPT dated on 2014-11-13: The Top 25 Analysts On Wall Street

Financial news for ICPT dated on 2014-11-08: Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis Presented at AASLD Annual Meeting

Financial news for ICPT dated on 2014-11-07: Mid-Afternoon Market Update: Lions Gate Surges On Earnings Beat; Abercrombie & Fitch Shares Decline

Financial news for ICPT dated on 2014-11-07: 4 Stocks Twitter Is Buzzing About

Financial news for ICPT dated on 2014-11-07: Midday Losers From November 7: Roka Bioscience, Salix Pharmaceuticals, Intercept Pharmaceuticals, Extended Stay America

Financial news for ICPT dated on 2014-11-07: Leerink Swann Downgrades Intercept to Market Perform, Lowers PT to \$191.00

Financial news for ICPT dated on 2014-11-07: Morning Market Losers

Financial news for ICPT dated on 2014-11-07: Intercept Shares Fall Almost 20% Premarket, as Lancet Report Cites Raised Bad Cholesterol Levels in Patients Receiving NASH Drug

Financial news for ICPT dated on 2014-11-07: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-11-06: FLINT Trial in NASH Published in The Lancet

Financial news for ICPT dated on 2014-11-06: Intercept Reports Q3 EPS of \$(1.69) vs \$(1.10) Est

Financial news for ICPT dated on 2014-11-04: Meet The 5 Companies Loving Obamacare

Financial news for ICPT dated on 2014-10-31: Intercept to Report Q3 2014 Results on November 7, 2014

Financial news for ICPT dated on 2014-10-08: Morning Market Losers

Financial news for ICPT dated on 2014-10-08: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-10-08: Intercept Data to be Presented at the 2014 AASLD Annual Meeting

Financial news for ICPT dated on 2014-09-16: Conatus Pharmaceuticals Shares Move Higher; May be Attributed to Seeking Alpha Post

Financial news for ICPT dated on 2014-09-05: Benzinga's Top Initiations

Financial news for ICPT dated on 2014-09-05: Cowen Initiates Intercept At Outperform

Financial news for ICPT dated on 2014-09-05: Cowen & Company Initiates Coverage on Intercept at Outperform, Announces \$420.00 PT

Financial news for ICPT dated on 2014-09-05: Cowen Starts Intercept Pharmaceuticals With Outperform; PT \$420 -Reuters

Financial news for ICPT dated on 2014-08-28: Intercept Spikes to Lows on Volume

Financial news for ICPT dated on 2014-08-27: Orbimed Advisors Sells 111,258 Shares of Intercept Pharmaceuticals @\$298.06/Share -Form 4

Financial news for ICPT dated on 2014-08-18: Intercept Pharmaceuticals Shareholder Orbimed Advisors Sells 60,000 Shares @\$299.82/Share -Form 4

Financial news for ICPT dated on 2014-08-15: Morning Market Losers

Financial news for ICPT dated on 2014-08-15: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-08-14: Shares of Intercept Moving Higher; Report of Tweet Mentioning Potential Deal by Gilead being Passed Around, Totally Unconfirmed

Financial news for ICPT dated on 2014-08-13: CNBC's Stock Pops & Drops From August 12

Financial news for ICPT dated on 2014-08-12: Markets Marginally Lower In Quiet Trading Session

Financial news for ICPT dated on 2014-08-12: #Premarket Prep Technical Update - Intercept Pharmaceuticals Trading Higher But Well Off Highs For The Session

Financial news for ICPT dated on 2014-08-12: U.S. Job Openings Climb; Leerink Swann Bullish On Intercept Pharmaceuticals

Financial news for ICPT dated on 2014-08-12: U.S. Stocks Fall; Dealertrack Shares Surge On Upbeat Results

Financial news for ICPT dated on 2014-08-12: Markets Mostly Flat; Flowers Foods Profit Misses Estimates

Financial news for ICPT dated on 2014-08-12: Benzinga's Volume Movers

Financial news for ICPT dated on 2014-08-12: Morning Market Movers

Financial news for ICPT dated on 2014-08-12: Conatus Shares Move Higher On Industry Data

Financial news for ICPT dated on 2014-08-12: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2014-08-12: Leerink Swann Upgrades Intercept to Outperform, Raises PT to \$445.00

Financial news for ICPT dated on 2014-08-11: Intercept Pharmaceutical's Shares Soar On Earnings

Financial news for ICPT dated on 2014-08-11: Intercept Pharma Shares Resume Trade, Now Up ~39%

Financial news for ICPT dated on 2014-08-11: PREVIEW: Intercept to Resume Trading at 4:40 PM ET

Financial news for ICPT dated on 2014-08-11: Intercept Pharmaceuticals Says INT-767 Phase 1 Trial Initiation Expected in H1 2015

Financial news for ICPT dated on 2014-08-11: Intercept Reports Q2 EPS of \$1.51; Revenue of \$445.0K vs \$400.0K Est

Financial news for ICPT dated on 2014-08-11: Intercept Pharma 10-Q Just Filed

Financial news for ICPT dated on 2014-08-11: Intercept Pharma Halted News Pending

Financial news for ICPT dated on 2014-07-25: Adam Feuerstein Tweet: After spending time with \$ICPT NASH study this week for Mailbag, \$GALT NASH trial is farce by comparison.

Financial news for ICPT dated on 2014-07-14: Dow Sets New Intraday High; Citigroup Impresses With Earnings

Financial news for ICPT dated on 2014-07-14: Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation

Financial news for ICPT dated on 2014-07-14: Deutsche Bank Initiates Coverage on Intercept at Buy, Announces \$395.00 PT

Financial news for ICPT dated on 2014-07-02: Markets Little Changed Ahead Of 4th Of July Break

Financial news for ICPT dated on 2014-07-02: Benzinga's Top Initiations

Financial news for ICPT dated on 2014-07-02: Goldman Sachs Initiates Coverage on Intercept at Neutral, Announces \$265.00 PT

Financial news for ICPT dated on 2014-06-30: RBC Capital Initiates Coverage on Intercept at Outperform, Announces \$425.00 PT

Financial news for ICPT dated on 2014-06-26: Markets Slightly Lower As Bullard Hints Higher Rates Could Come Sooner Than Expected

Financial news for ICPT dated on 2014-06-26: Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following FLINT Data Delay

Financial news for ICPT dated on 2014-06-26: Hearing Summer Street Reiterates Buy and \$650 PT on Intercept on Potential FDA Breakthrough Therapy Designation for NASH

Financial news for ICPT dated on 2014-06-26: Leerink Swann Initiates Coverage on Intercept at Market Perform, Announces \$270.00 PT

Financial news for ICPT dated on 2014-06-26: Nomura Initiates Coverage on Intercept at Neutral, Announces \$294.00 PT

Financial news for ICPT dated on 2014-06-09: Top Healthcare Movers For June 9, 2014

Financial news for ICPT dated on 2014-05-29: Market Wrap For May 29: Investors Welcome Another Record High For The S&P 500

Financial news for ICPT dated on 2014-05-29: Morning Market Movers

Financial news for ICPT dated on 2014-05-29: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2014-05-28: Shares of Intercept Pharma Spike Nearly \$20 Following Fast Track News, Now Up ~7.7% in Post-Market Trade

Financial news for ICPT dated on 2014-05-28: UPDATE: Intercept Announces FDA Fast Track Designation to Obeticholic Acid for Treatment of Primary Biliary Cirrhosis

Financial news for ICPT dated on 2014-05-28: Intercept Announces FDA Fast Track Designation to Obeticholic Acid for Treatment of Primary Biliary Cirrhosis

Financial news for ICPT dated on 2014-05-28: Citi Analyst Defends Intercept Pharmaceuticals

Financial news for ICPT dated on 2014-05-22: Investors in Intercept Pharma Cheer Co.'s Disclosure of Emails Related to FLINT Trial, Shares Up More Than 4% at Last Check

Financial news for ICPT dated on 2014-05-21: Intercept Shares Rebound 4% Premarket; May be Attributed to Oppenheimer Defense

Financial news for ICPT dated on 2014-05-20: Market Wrap For May 20: Markets Sharply Lower On Fed Talk, Disappointing Earnings

Financial news for ICPT dated on 2014-05-20: Intercept Pharmaceuticals Tumbles On Safety Concern Allegations

Financial news for ICPT dated on 2014-05-20: Morning Market Losers

Financial news for ICPT dated on 2014-05-20: Adam Feuerstein Tweet: 'SummerStreet defends \$ICPT. Nothing to see here. reiterates \$650 PT'

Financial news for ICPT dated on 2014-05-20: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-05-20: Intercept Pharma Shares Plunge 14+% as TheStreet's Adam Feuerstein Reports 'Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show'

Financial news for ICPT dated on 2014-05-20: Intercept Shares Fall 15% Premarket

Financial news for ICPT dated on 2014-05-20: Adam Feuerstein Tweet: '\$ICPT, Government Scientists, Spar Over Negative Safety of Liver Drug, Emails Show'

Financial news for ICPT dated on 2014-05-19: Late Afternoon Market Movers

Financial news for ICPT dated on 2014-05-15: Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Financial news for ICPT dated on 2014-05-15: Summer Street Initiates Coverage on Intercept at Buy, Announces \$650.00 PT

Financial news for ICPT dated on 2014-05-07: Intercept Reports Q1 Revenue of \$405.0K vs \$400.0K Est

Financial news for ICPT dated on 2014-05-06: Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week

Financial news for ICPT dated on 2014-04-14: Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

Financial news for ICPT dated on 2014-04-12: Intercept Announces Additional Positive Data from POISE Trial at EASL

Financial news for ICPT dated on 2014-04-11: Intercept Issues Preclinical Data Showing OCA's Potential Role in Preventing Complications of Cirrhosis

Financial news for ICPT dated on 2014-04-10: Jon Gardner tweets: 'Just spoke with \$ICPT CEO Pruzanski, who says the company has not hired Rachel "\$800 Price Target" McMinn. #ILC2014'

Financial news for ICPT dated on 2014-04-10: Intercept Will Not Need Partner for Phase 3 NASH Trial, Co. Share Sale Will Fund Trial, Launch for PBC - Bloomberg

Financial news for ICPT dated on 2014-04-04: Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform

Financial news for ICPT dated on 2014-04-04: Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014

Financial news for ICPT dated on 2014-04-04: Intercept Announces Will Present Data from PIVOTAL Phase 3 POISE Trial of FXR Agonist Obeticholic Acid at EASL 2014 Apr. 9-13th

Financial news for ICPT dated on 2014-04-04: US Stock Futures Nudge Higher Ahead Of Jobs Data

Financial news for ICPT dated on 2014-04-04: UPDATE: Intercept Shares Rise More than 1% Premarket Following Announcement of Pricing of 1M Share Offering at \$320/Share

Financial news for ICPT dated on 2014-04-04: Intercept Pharmaceuticals Prices 1M Share Offering at \$320.00/Share



Financial news for ICPT dated on 2014-04-03: Amended 13G Filing from SAC Capital on Intercept Pharma Shows Less Than 0.1% Stake, Had Shown 6.4% Stake as of Dec. 31st

Financial news for ICPT dated on 2014-04-01: Intercept Pharma Reports Proposed Offering for 1M Shares, 400K Through Selling Holders, 600K by the Co.

Financial news for ICPT dated on 2014-03-17: Market Wrap For March 17: Investors Focused On Economic Data Instead Of Crimea Concerns

Financial news for ICPT dated on 2014-03-17: Intercept Pharmaceuticals Announces Q4 Earnings

Financial news for ICPT dated on 2014-03-17: Intercept Pharmaceuticals Trading Sharply Lower

Financial news for ICPT dated on 2014-03-17: Needham Lifts Target on Intercept Pharma from \$320 to \$500

Financial news for ICPT dated on 2014-03-17: Shares of Intercept Pharma Moving Lower as Hearing Oppenheimer Analyst Has Said Expecting an Equity Offering Soon

Financial news for ICPT dated on 2014-03-17: Hearing Oppenheimer Says Intercept Likely to do Secondary Offering

Financial news for ICPT dated on 2014-03-17: Top Trending Tickers On StockTwits For March 17

Financial news for ICPT dated on 2014-03-17: From Intercept Call: Noting Serious Adverse Events Were Split Between Groups, One Event Was in Placebo, Other Was in Drug Group

Financial news for ICPT dated on 2014-03-17: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-03-16: Intercept Announces Phase 3 POISE Trial Met Primary Endpoint

Financial news for ICPT dated on 2014-03-14: Intercept Reports Q4 EPS of \$(0.64) vs \$(0.70) Est

Financial news for ICPT dated on 2014-03-14: BioBreakthrough's Tweet: \$GLMD virgin NASH play likely to attract some serious attention as \$ICPT tests all-time highs

Financial news for ICPT dated on 2014-03-14: Morning Gainers for Friday, March 14, 2014

Financial news for ICPT dated on 2014-03-13: Biotech ETFs Flash Buy Signals (XBI, IBB, BBH, ICPT)

Financial news for ICPT dated on 2014-03-10: Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up

Financial news for ICPT dated on 2014-02-25: Intercept Spikes Higher

Financial news for ICPT dated on 2014-02-18: Intercept Names Sanj K. Patel and Glenn Sblendorio to Board of Directors

Financial news for ICPT dated on 2014-02-11: Which Sector Produced 8 Of The 10 Top Percentage Gainers In 2014?

Financial news for ICPT dated on 2014-02-10: Market Wrap For February 10: Markets Cautious Ahead Of Yellen Testimony

Financial news for ICPT dated on 2014-01-17: Rise in Intercept Shares May be Attributed to Report of 'A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis'

Financial news for ICPT dated on 2014-01-17: Intercept Spikes Higher

Financial news for ICPT dated on 2014-01-15: Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy

Financial news for ICPT dated on 2014-01-15: Mid-Morning Market Update: Markets Rise; Bank of America Profit Beats Estimates

Financial news for ICPT dated on 2014-01-15: Adam Feuerstein Tweet \$ICPT mentions \$RPTP and \$GILD as NASH competitors. #JPM14

Financial news for ICPT dated on 2014-01-15: Intercept Pharma Shares Volatile as CEO Pruzanski Speaking at JP Morgan Healthcare Conf., Says Expecting OCA Final Results

Issued in Q4

Financial news for ICPT dated on 2014-01-15: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2014-01-15: Intercept Shares Rise 5% Pre-Market on Bank of America Reiteration of \$872 PT, Buy Rating

Financial news for ICPT dated on 2014-01-14: Hearing Bank of America Reiterates Buy Rating and \$872 PT on Intercept

Financial news for ICPT dated on 2014-01-14: Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

Financial news for ICPT dated on 2014-01-14: Mid-Afternoon Market Update: Markets Continue Rally as Tesla Guidance Lifts Stock

Financial news for ICPT dated on 2014-01-14: Hearing BMO Defending ICPT

Financial news for ICPT dated on 2014-01-14: Hearing Positive Comments from Summer Street on Intercept

Financial news for ICPT dated on 2014-01-13: Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases

Financial news for ICPT dated on 2014-01-13: Morning Market Losers

Financial news for ICPT dated on 2014-01-13: Benzinga's Top #PreMarket Losers

Financial news for ICPT dated on 2014-01-13: Intercept Shares Fall 31% in Pre-Market to \$308.10, Following Late Friday WSJ Article: 'NIH Says Patients on Intercept Drug Had More 'Bad' Cholesterol'

Financial news for ICPT dated on 2014-01-12: Intercept Reports Additional Details About FLINT Clinical Trial of OCA in NASH Provided by NIDDK

Financial news for ICPT dated on 2014-01-11: Intercept Shares Fall \$25 After-Hours on WSJ Article: 'NIH Says Patients on Intercept Drug Had More 'Bad' Cholesterol'

Financial news for ICPT dated on 2014-01-10: Intercept to Present at the JP Morgan Healthcare Conference on Wednesday, January 15, 2014 at 10:30 AM ET

Financial news for ICPT dated on 2014-01-10: Clovis Shares Spike Higher After-Hours on CNBC Comments it is Next Intercept

Financial news for ICPT dated on 2014-01-10: Market Wrap For January 10: Job Growth Weak, But Unemployment Falls

Financial news for ICPT dated on 2014-01-10: Mid-Afternoon Market Update: Plug Rises on Secondary Pricing as Markets Remain Mixed Following Jobs Number

Financial news for ICPT dated on 2014-01-10: 13G Filing from Visium Asset Mgmt on Intercept Pharma Shows Raised Stake from 3.97% Stake as of Sept. 30th to 5.3% Stake

Financial news for ICPT dated on 2014-01-10: Mid-Day Market Update: Abercrombie & Fitch Surges On Strong Outlook; Sears Shares Slip

Financial news for ICPT dated on 2014-01-10: Mid-Morning Market Update: Markets Drop; Alcoa Q4 Earnings Miss Estimates

Financial news for ICPT dated on 2014-01-10: Bank of America Reiterates on Intercept Pharmaceuticals

Financial news for ICPT dated on 2014-01-10: Benzinga's Volume Movers

Financial news for ICPT dated on 2014-01-10: Stocks Hitting 52-Week Highs

Financial news for ICPT dated on 2014-01-10: Citi Maintains on Intercept Pharmaceuticals

Financial news for ICPT dated on 2014-01-10: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2014-01-10: Bank of America Maintains Buy on Intercept, Raises PO to \$872.00

Financial news for ICPT dated on 2014-01-10: Oppenheimer Maintains Outperform on Intercept, Raises PT to \$360.00

Financial news for ICPT dated on 2014-01-10: Citigroup Maintains Buy on Intercept, Raises PT to \$400.00

Financial news for ICPT dated on 2014-01-09: Market Wrap For January 9: All Eyes on Tomorrow's Job Report

Financial news for ICPT dated on 2014-01-09: Mid-Afternoon Market Update: Markets Moving Sideways Ahead of Alcoa Report

Financial news for ICPT dated on 2014-01-09: Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings

Financial news for ICPT dated on 2014-01-09: Benzinga's Volume Movers

Financial news for ICPT dated on 2014-01-09: Morning Market Movers

Financial news for ICPT dated on 2014-01-09: Benzinga's Top #PreMarket Gainers

Financial news for ICPT dated on 2014-01-09: Intercept Shares Resume Trading, Now Up 119%

Financial news for ICPT dated on 2014-01-09: Shares of Intercept Pharma to Resume Trade at 8AM EST

Financial news for ICPT dated on 2014-01-09: UPDATE: Intercept Cites Highly Statistically Significant Improvement

Financial news for ICPT dated on 2014-01-09: Intercept Reports Nash Primary Endpoint Met, FLINT Trial Has Been Stopped Early

Financial news for ICPT dated on 2014-01-09: Intercept Pharma Shares Halted News Pending

Financial news for ICPT dated on 2014-01-02: Intercept Says Extended Term of Research Program with Servier to Sept. 30th, 2015

Financial news for ICPT dated on 2014-01-02: Intercept Pharma Says Will Issue Update on Obeticholic Acid Program Jan. 9th

Financial news for ICPT dated on 2013-11-08: 13G Filing from SAC Capital on Intercept Pharma Shows 5.3% Stake

Financial news for ICPT dated on 2013-10-24: Intercept Pharmaceutical Shares Skyrocket after Oppenheimer's Data "Optimism"

Financial news for ICPT dated on 2013-10-09: Intercept Prices 1.5M Share Offering at \$62.50/Share

Financial news for ICPT dated on 2013-10-01: S-1 Filing from Intercept Pharma Shows Holders to Sell Shares

Financial news for ICPT dated on 2013-08-14: UPDATE: BMO Capital Markets Raises PT on Intercept Pharmaceuticals Following 2Q13 Operating Results

Financial news for ICPT dated on 2013-08-13: UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals Following In-Line Q2 Financials

Financial news for ICPT dated on 2013-08-13: Intercept Reports Q2 EPS of \$(0.79) vs \$(0.51) Est; Revenue of \$405.0K vs \$400.0K Est

Financial news for ICPT dated on 2013-08-12: Citigroup Initiates Coverage on Intercept at Buy, Announces \$60.00 PT

Financial news for ICPT dated on 2013-07-02: BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets

Financial news for ICPT dated on 2013-06-24: ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)

Financial news for ICPT dated on 2013-06-24: Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares

Financial news for ICPT dated on 2013-06-21: UPDATE: Oppenheimer Initiates Intercept Pharmaceuticals at Outperform on Bullish Outlook

Financial news for ICPT dated on 2013-06-20: Oppenheimer Initiates Coverage on Intercept at Outperform, Announces \$60.00 PT

Financial news for ICPT dated on 2013-06-19: Mid-Afternoon Market Update: Markets Fall Following FOMC Statement; Adobe Remains on the Rise

Financial news for ICPT dated on 2013-06-19: Mid-Day Market Update: La-Z-Boy Drops On Q4 Results, Nektar Gains

Financial news for ICPT dated on 2013-06-19: Mid-Morning Market Update: Markets Edge Lower, FedEx Posts Upbeat Profit

Financial news for ICPT dated on 2013-06-19: Intercept Pharmaceuticals Prices 1.73M Share Offering at \$33.01/Share

Financial news for ICPT dated on 2013-06-17: Intercept Pharmaceuticals Announces 1.73M Share Offering

Financial news for ICPT dated on 2013-06-10: Intercept Pharma Registers Up to 2M Shares for ~\$63.3M

Financial news for ICPT dated on 2013-05-14: Intercept Reports Q1 EPS of \$(0.62) Which May Not Compare \$(0.44) Est

Financial news for ICPT dated on 2013-04-30: Intercept Issues Added Results of Global Primary Biliary Cirrhosis Study, Says Ursodiol Failed to Meet Poise Endpoint in 59% of Patients

Financial news for ICPT dated on 2013-04-15: UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals on Decreased Regulatory Risk

Financial news for ICPT dated on 2013-04-15: Wedbush Maintains Outperform on Intercept, Raises PT to \$56.00

Financial news for ICPT dated on 2013-03-18: Intercept Reports Q4 EPS of \$(2.02) Which May Not Compare \$(0.34) Est

Financial news for ICPT dated on 2013-01-07: Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan

Financial news for ICPT dated on 2012-12-19: Intercept Pharmaceuticals Completes Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial

Financial news for ICPT dated on 2012-11-12: UPDATE: Bank of America Initiates Intercept Pharmaceuticals at Buy on Regulatory Outlook

Financial news for ICPT dated on 2012-11-12: Bank of America Initiates Coverage on Intercept Pharmaceuticals at Buy, Announces PO of \$29

Financial news for ICPT dated on 2012-11-08: Intercept Pharma Announces OCA Well Tolerated, Says 5 Patients Met Primary Efficacy Point

Financial news for ICPT dated on 2012-11-08: Wedbush Securities Initiates Coverage on Intercept Pharmaceuticals at Outperform, Announces PT of \$25

Financial news for ICPT dated on 2012-11-05: UPDATE: BMO Capital Markets Initiates Intercept Pharmaceuticals at Outperform on Outlook

Financial news for ICPT dated on 2012-11-01: Stocks Hitting 52-Week Lows

Financial news for ICPT dated on 2012-10-11: Intercept Opens for Trading at \$18.49, Priced at \$15 per Share